  Vortioxetine is an antidepressant agent with multimodal activity that is approved for the treatment of major depressive disorder at doses of 5 to 20 mg once daily. Vortioxetine is a medium-clearance drug that undergoes extensive metabolism via several cytochrome P450 isozymes. A series of single- and multiple-dose pharmacokinetic studies were performed to evaluate the impact of intrinsic ( ie , subject-related) factors , such as age , sex , race , and renal and hepatic function , on the pharmacokinetics of vortioxetine. The point estimates on the ratios and their 90 % confidence intervals ( CIs) for the central values of AUC ( area under the concentration-time curve) and C